AN EXTENSION OF BBIL/CTP/04/2010 PHASE 3 CLINICAL TRIAL OF TYPBAR TCVA: To DETERMINE THE LEVEL OF ANTI-SALMONELLA TYPHI VI POLYSACCHARIDE IGG ANTIBODIES AT THE END OF APPROXIMATELY 7 YEARS AND FOLLOW UP OF A BOOSTER DOSE OF TYPBAR TCVA DOSE IN THOSE WHO HAVE LOWER LEVEL OF ANTIBODIES (BELOW CORRELATE OF PROTECTION) IN HEALTHY PRIMED AND BOOSTER DOSE RECEIVED CHILDREN AND ADULTS - Typbar TCVA 7 years followup study
Latest Information Update: 26 Sep 2019
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary)
- Indications Typhoid
- Focus Pharmacodynamics
- Sponsors Bharat Biotech
Most Recent Events
- 26 Sep 2019 New trial record